Galux: Scaling AI-designed biologics

Galux believes it can reimagine how biologics are designed for both precision and scale, combining generative AI with high-throughput screening and experimental validation — an effort fueled by Monday’s fresh cash infusion of a $29 million series B raise.

Founded in 2020 by Seoul National University professor Chaok Seok and three of her graduate students, Galux Inc. has been active in recent months, disclosing an AI-driven protein discovery collaboration with Boehringer Ingelheim GmbH in December and the Yuanta Investment-led Series B on Monday...